Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Googling migraine: A study of Google as an information resource of migraine management

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Oral rimegepant for migraine prevention

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Kristian A Haanes
  • Alejandro Labastida-Ramírez
  • Frank W Blixt
  • Eloisa Rubio-Beltrán
  • Clemens M Dirven
  • Alexander Hj Danser
  • Lars Edvinsson
  • Antoinette MaassenVanDenBrink
Vis graf over relationer

BACKGROUND: The current understanding of mechanisms behind migraine pain has been greatly enhanced with the recent therapies targeting calcitonin gene-related peptide and its receptor. The clinical efficacy of calcitonin gene-related peptide-blocking drugs indicates that, at least in a considerable proportion of patients, calcitonin gene-related peptide is a key molecule in migraine pain. There are several receptors and molecular pathways that can affect the release of and response to calcitonin gene-related peptide. One of these could be purinergic receptors that are involved in nociception, but these are greatly understudied with respect to migraine.

OBJECTIVE: We aimed to explore purinergic receptors as potential anti-migraine targets.

METHODS: We used the human middle meningeal artery as a proxy for the trigeminal system to screen for possible anti-migraine candidates. The human findings were followed by intravital microscopy and calcitonin gene-related peptide release measurements in rodents.

RESULTS: We show that the purinergic P2Y13 receptor fulfills all the features of a potential anti-migraine target. The P2Y13 receptor is expressed in both the human trigeminal ganglion and middle meningeal artery and activation of this receptor causes: a) middle meningeal artery contraction in vitro; b) reduced dural artery dilation following periarterial electrical stimulation in vivo and c) a reduction of CGRP release from both the dura and the trigeminal ganglion in situ. Furthermore, we show that P2X3 receptor activation of the trigeminal ganglion causes calcitonin gene-related peptide release and middle meningeal artery dilation.

CONCLUSION: Both an agonist directed at the P2Y13 receptor and an antagonist of the P2X3 receptor seem to be viable potential anti-migraine therapies.

TidsskriftCephalalgia : an international journal of headache
Udgave nummer11
Sider (fra-til)1421-1434
Antal sider14
StatusUdgivet - okt. 2019

ID: 57526504